The contract begins with up to 665,000 doses of the vaccine manufactured by CSL Seqirus and has an option for an additional 40 million doses for a maximum of four years.
People who work with poultry and veterinarians are considered at greatest risk, but there have been no cases in Europe and only three involving cattle in the United States.
CSL Seqirus is at Melbourne, Australia.
